

REC
JCO6 Rec'd PCT/PTO 30 SEP 2005

DOC NO.: CELL-0293/PA523-USW01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Daniel Christopher Brookings, Rachel

Jane Cubbon, Jeremy Martin Davis,

Barry John Langham

Confirmation No.: 6765

Application No.: 10/529,413

Group Art Unit: 1642

Filing Date: June 23, 2005

Examiner: Not yet assigned

For: Bicyclic Heteroaromatic Compounds As Kinase Inhibitors

DATE OF DEPOSIT: *September 28, 2005*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jane E. Inglese

TYPED NAME: Jane E. Inglese
REGISTRATION NO.: 48,444

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE**

In response to the "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated **August 31, 2005**, a response to which is due **October 31, 2005**, enclosed herewith is:

- ☐ Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825;
- ☐ Substitute pages of the Sequence Listing;
- ☐ Substitute copy of the computer readable form of amended Sequence Listing;
- ☐ Amendment Directing Entry of Sequence Listing into Specification is attached
- ☐ Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- ☒ Other: **A Communication to the Patent Office**
- ☐ Request is hereby made under 37 CFR § 1.136(a) to extend the time for response to the Notice to File Missing Parts of Application of _____ to and through _____, comprising an extension of the shortened period of _____ months:

	SMALL ENTITY		NOT SMALL ENTITY	
	RATE	FEE	RATE	FEE
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME	\$60	\$	\$120	\$
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME	\$225	\$	\$450	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME	\$510	\$	\$1020	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME	\$795	\$	\$1590	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME	\$1080	\$	\$2160	\$
TOTAL FEE DUE		\$0		\$0

Applicant(s) has/have not been notified that the requested extension will not be permitted. The present application is not involved in an interference declared pursuant to 37 CFR § 1.207.

Total fee required \$.00

DOCKET NO.: CELL-0293/PA523-USW01 - 3 -

PATENT

- ☐ The Commissioner is hereby authorized to charge any deficiency or credit any overpayment of the fees associated with this communication to Deposit Account No. 23-3050.


Date: *September 28, 2005*

Jane E. Inglese

Jane E. Inglese
Registration No. 48,444

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW



Rec'd 10/PTO 30 SEP 2005

PATENT #7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Brookings, D.C., et al.

Confirmation No.: 6765

Application No.: 10/529,413

Group Art Unit: 1642

Filing Date: June 23, 2005

Examiner: Not yet assigned

For: **Bicyclic Heteroaromatic Compounds As Kinase Inhibitors**

DATE OF DEPOSIT: September 28, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jane E. Inglese

TYPED NAME: Jane E. Inglese
REGISTRATION NO.: 48,444

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**COMMUNICATION IN RESPONSE TO THE NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

A "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" was issued **August 31, 2005** in connection with the above-referenced patent application. The application, however, does

DOCKET NO.: CELL-0293/PA523-USW01
Application No.: 10/529,413

PATENT


not contain nucleotide or amino acid sequences. Accordingly, Applicants are not required to submit a Sequence Listing for the application.

Respectfully submitted,

Date: *September 28, 2005*

Jane E. Inglese
Jane E. Inglese
Registration No. 48,444

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



RECEIVED

SEP 06 2005

DOCKET DEPT
WWKMNREC PCT/PTO 30 SEP 2005
DAC/TEI (C)UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/529,413	Daniel Christopher Brookings	Cell-0293

INTERNATIONAL APPLICATION NO.
PCT/GB03/04214

I.A. FILING DATE	PRIORITY DATE
09/30/2003	10/01/2002

23377
WOODCOCK WASHBURN LLP
ONE LIBERTY PLACE, 46TH FLOOR
1650 MARKET STREET
PHILADELPHIA, PA 19103

RECEIVED

SEP 03 2005

Woodcock Washburn

CONFIRMATION NO. 6765
371 FORMALITIES LETTER
OC000000016885207
OC000000016885207

Date Mailed: 08/31/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- o This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- o A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- o For Rules Interpretation, call (571) 272-0951
- o For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- o Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/529,413	PCT/GB03/04214	Cell-0293

FORM PCT/DO/EO/922 (371 Formalities Notice)